View Older Stories View More Recent Stories
-
Lumos Pharma (LUMO) Says Data Supporting Use of Predictive Enrichment Markers for its LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Empire BlueCross BlueShield Partners with On-Demand Healthcare Service Ready to Provide New York City Residents Medical Care in Their Homes
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
-
Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases
-
Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
-
Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
-
Valneva Reports FY 2020 Results and Major Corporate Achievements
-
Valneva Reports FY 2020 Results and Major Corporate Achievements
-
Independence Blue Cross and Quartet Health Collaborate to Address Behavioral Health
-
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Lumos Pharma Announces Changes to its Board of Directors
-
Lumos Pharma Announces Changes to its Board of Directors
-
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
-
ConcertoHealth and Perfect Health Are Now ConcertoCare
-
Sema4 to Combine with SPAC, CM Life Sciences (CMLF)
-
Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth
-
Dana-Farber Cancer Institute and Deerfield Management Launch Riverway Discoveries
-
Pairwise Raises $90 Million to Bring New Varieties of Fruits and Vegetables to Market
-
SpectraWAVE Announces $13.2 Million Series A-2 Financing from Existing Investors to Bring Intracoronary Imaging Technology to Market
-
Encodia Closes $75M Series C Financing Led by Northpond Ventures and Deerfield Management
-
Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
-
COVID Test Results in 15min with New At-Home Test Service from Ready
-
MIVI Neuroscience Secures Series B Funding
-
Terns Announces FDA Clearance of Investigational New Drug (IND) Application for First-in-Human Phase 1 Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
-
Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms
-
Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms
-
Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients
-
Avidity Biosciences Announces Changes to its Board of Directors
-
Blade Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Valneva Reports FY 2020 Cash of Over €200 Million
-
Valneva Reports FY 2020 Cash of Over €200 Million
-
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
-
Terns Appoints Three New Independent Directors to its Board
-
Terns Closes $87 Million Series C Financing to Advance NASH Portfolio
-
Form 13F-HR/A DEERFIELD MANAGEMENT For: Sep 30
-
Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs
-
Deerfield Launches a Novel Funding Mechanism, the X-Seed Award, to Support Early-Stage Life Sciences and Underrepresented Company Founders
-
Deerfield Launches a Novel Funding Mechanism, the X-Seed Award, to Support Early-Stage Life Sciences and Underrepresented Company Founders
-
Form SC 13D/A Deerfield Healthcare Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Deerfield Healthcare Technology Acquisitions (DFHT) Announces Proposed Business Combination to Form CareMax
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Proposed Business Combination to Form CareMax
-
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference
-
Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference

